Compare
Alpha Teknova, Inc. vs Immucell Corp vs Aspira Women's Health Inc. vs Myriad Genetics Inc
| Latest fiscal year | Alpha Teknova, Inc. TKNO | Immucell Corp ICCC | Aspira Women's Health Inc. AWHL | Myriad Genetics Inc MYGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $40.52M | $27.64M | $9.22M | $824.50M |
| Revenue growth (YoY) | +7.4% | +4.3% | +0.4% | -1.6% |
| Gross margin | 33.2% | 41.4% | 64.2% | 69.9% |
| Operating margin | -41.9% | 6.0% | -85.9% | -47.0% |
| Net margin | -42.6% | -3.8% | -138.7% | -44.4% |
| Net income | -$17.26M | -$1.04M | -$12.78M | -$365.90M |
| EPS (Diluted) | -$0.32 | -$0.12 | -$0.37 | -$3.95 |
| Operating cash flow | -$8.65M | $2.48M | -$7.03M | $1.80M |
| Free cash flow | -$9.79M | $1.22M | -$7.04M | n/a |
| Cash & equivalents | $5.91M | $3.81M | $1.75M | $149.60M |
| Total assets | $103.58M | $42.53M | $5.46M | $706.60M |
| Total liabilities | $34.81M | $15.48M | $12.39M | $338.60M |
| Shareholders' equity | $68.78M | $27.06M | -$6.93M | $368.00M |
| Return on year-end equity | -25.1% | -3.8% | n/a | -99.4% |
| Shares outstanding | 53.56M | 9.05M | 43.48M | 93.50M |
Revenue, most recent five fiscal years
| Fiscal year | Alpha Teknova, Inc. | Immucell Corp | Aspira Women's Health Inc. | Myriad Genetics Inc |
|---|---|---|---|---|
| Latest | $40.52M Ended 2025-12-31 | $27.64M Ended 2025-12-31 | $9.22M Ended 2025-12-31 | $824.50M Ended 2025-12-31 |
| 1 year earlier | $37.74M Ended 2024-12-31 | $26.49M Ended 2024-12-31 | $9.18M Ended 2024-12-31 | $837.60M Ended 2024-12-31 |
| 2 years earlier | $36.68M Ended 2023-12-31 | $17.47M Ended 2023-12-31 | $9.15M Ended 2023-12-31 | $753.20M Ended 2023-12-31 |
| 3 years earlier | $41.42M Ended 2022-12-31 | $18.57M Ended 2022-12-31 | n/a | $678.40M Ended 2022-12-31 |
| 4 years earlier | $36.89M Ended 2021-12-31 | $19.24M Ended 2021-12-31 | n/a | $690.60M Ended 2021-12-31 |